This program consists of one-hour podcasts where we interview top AML researchers on their open clinical trials and other key AML news topics.
Each article will include background information on the AML researcher, a summary of the radio show, the full radio recording so you can listen to the entire show whenever you want, and a written transcript in case you would rather read the interview.
Our radio shows are great for AML patients who are interested in learning about the most cutting-edge AML research. These shows go beyond the basic question of "what is AML" and really explain all the ins and outs of AML in great detail. By listening, you are able to learn about which AML research trials you may be able to participate in. Be on the lookout for announcements on our upcoming radio shows so that you can mark your calendar and listen live!
HealthTree Radio for AML —September 22, 2021
Join us live on September 30th at 12 PM Central to learn from Dr. Reagan, an AML specialist from Lifespan Cancer Institute at Rhode Island Hospital about what steps you can take if you have relapsed or refractory AML. He will be discussing what immunotherapy is, it’s current use in AML and his open clinical trial looking at whether the FDA approved drug gemtuzumab, followed by an infusion of blood cells called leukocytes from a donor, can stimulate the immune system to potentially fight AML.
HealthTree Radio for AML —September 20, 2021
Listen to the full recording of our conversation with Dr. Gabriel Mannis, an AML expert from the Stanford Cancer Institute in California about how hypomethylating agents and venetoclax have become the new standard of care for older individuals with AML and his open clinical trial looking at what could become the first all oral therapy for newly diagnosed AML.
HealthTree Radio for AML —August 26, 2021
Announcing HealthTree for AML Radio, a podcast style series of interviews with top AML experts about their open clinical trials! Join us for our first radio show on 9/13 with Dr. Mannis of the Stanford Cancer Center to learn about treatment options for older adults and his open trial evaluating what could be the first all oral therapy for newly diagnosed older adults with AML.